BSGM - BioSig Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.99
+0.11 (+2.84%)
As of 12:04PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.88
Open3.98
Bid3.90 x 1800
Ask4.00 x 800
Day's Range3.98 - 4.22
52 Week Range1.28 - 7.13
Volume10,951
Avg. Volume83,075
Market Cap66.489M
Beta (3Y Monthly)1.06
PE Ratio (TTM)N/A
EPS (TTM)-1.29
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.63
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    BioSig Technologies Announces New Research Program with Mayo Clinic

    The new program will be run under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic’s Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory. The program will consist of a number of two-to three-year projects, which will focus on development of additional advanced features of PURE EP(tm) System within the field of electrophysiology and potential clinical applications of BioSig’s technology in a new, previously unexplored, field.

  • GlobeNewswire7 days ago

    BioSig Technologies to Ring NASDAQ Opening Bell on November 13, 2018

    Santa Monica, CA, Nov. 12, 2018 -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal.

  • GlobeNewswire19 days ago

    BioSig Technologies Opens Business Office in Norwalk, CT

    The new office will complement the Company’s headquarters in Los Angeles, CA and administration and finance office in Austin, TX. Norwalk office becomes the Company’s first location on the East Coast and will serve as the commercialization, sales support, investor relations and business development location.

  • GlobeNewswire21 days ago

    BioSig Technologies to Present at the 4th Annual Dawson James Small Cap Growth Conference

    BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced today that it will be presenting at the 4th annual Dawson James Small Cap Growth Conference. Mr. Kenneth Londoner, Founder, Chairman & CEO of BioSig Technologies, Inc., will do a presentation on October 30th on the Company’s progress, including recent uplist to Nasdaq, the FDA 510(k) clearance for the Company’s proprietary PURE EP(TM) System, as well as other business highlights.

  • Zacks Small Cap Research25 days ago

    BSGM: PURE EP Launch Timing Aligns Well With Attractive Market Fundamentals

    BioSig Technologies Inc. (BSGM) is a medical device company engaged in the development and commercialization of a proprietary signal processing platform designed to significantly improve real-time information and clinical decision-making in the ~$4B - $5B electrophysiology (EP) market. Following receipt of FDA 510(k) clearance in early August and subsequently uplisting their shares to Nasdaq, BioSig is readying for launch of the PURE EP System while simultaneously ramping up investor outreach efforts. In late August they hired Amy Scott, a seasoned medical device professional with more than two decades’ experience in the electrophysiology space, to lead the launch.

  • Zacks Small Cap Research2 months ago

    BSGM: PURE EP Poised For Strong U.S. Launch

    Following receipt of FDA 510(k) clearance in early August and uplisting their shares to Nasdaq, BioSig Technologies Inc. (BSGM) is readying for launch of their flagship product, the PURE EP System, and simultaneously ramping up investor outreach efforts. BioSig is a medical device company engaged in the development and commercialization of a proprietary signal processing platform designed to significantly improve real-time information and clinical decision-making in the ~$4B - $5B electrophysiology (EP) market. When drug therapy fails to control certain complex heart conditions such as atrial fibrillation and ventricular tachycardia, cardiologists often turn to catheter ablation.

  • GlobeNewswire2 months ago

    BioSig Technologies Retains Gilmartin Group for Investor Relations

    “We are delighted to engage the team at Gilmartin Group as investor relations advisors. BioSig places a high priority on shareholder value and I am confident that Gilmartin’s extensive experience in capital markets, combined with their deep expertise in the healthcare technology sector makes them an ideal partner as we seek to raise visibility of BioSig within the investment community,” stated Mr. Kenneth Londoner, Chairman and CEO of BioSig Technologies.

  • GlobeNewswire2 months ago

    BioSig Technologies Begins Trading on Nasdaq

    BioSig Technologies, Inc. (BSGM) a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that shares of its common stock have begun officially trading on the Nasdaq Capital Market, under the ticker “BSGM”. BioSig’s listing on the Nasdaq is the Company’s most recent operational achievement. In August 2018, the Company received 510(k) clearance from the FDA for their patented advanced signal acquisition and processing technology, PURE EP(tm) System.

  • GlobeNewswire2 months ago

    BioSig Technologies to Commence Trading on the Nasdaq

    BioSig Technologies, Inc. (OTCQB:BSGM, OTCQB:BSGMD), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced that its shares of common stock have been approved for trading on the Nasdaq Capital Market, commencing on Friday, September 21. “We are extremely pleased to be stepping onto the Nasdaq Capital Market at this pivotal point,” stated Mr. Kenneth Londoner, Chairman and CEO of BioSig Technologies.

  • GlobeNewswire2 months ago

    BioSig Technologies Issues Shareholder Letter

    BioSig Technologies, Inc. (OTCQB:BSGM, OTCQB:BSGMD) a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has issued their September 2018 letter to its shareholders providing them with updates on FDA 510(k) clearance, commercialization efforts, strategic relationships and enhancements to capital structure.

  • GlobeNewswire2 months ago

    BioSig Technologies, Inc. Announces 1-for-2.5 Reverse Stock Split for Pending Uplist to Nasdaq

    BioSig Technologies, Inc. (OTCQB: BSGM, OTCQB: BSGMD) (“BioSig” or the “Company”),  a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company will effect a reverse stock split of its issued and outstanding common stock at an exchange ratio of 1-for-2.5, after the close of business on Monday, September 10, 2018. The Company's common stock will begin trading on split-adjusted basis on Tuesday, September 11, 2018, under a new CUSIP number 09073N 201, and  the Company's symbol on the OTCQB  will change to “BSGMD” for a period of 20 business days, after which the "D" will be removed from the Company's trading symbol, which will revert to the original symbol of "BSGM".

  • GlobeNewswire3 months ago

    BioSig Technologies to Present at the MicroCap Leadership Summit

    BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that it has been selected to present at the third annual MicroCap Leadership Summit, hosted by MicroCapClub, on Friday, September 28, 2018, at the Westin Chicago Northwest Hotel in Itasca, Illinois. Mr. Kenneth Londoner, Founder, Chairman & CEO of BioSig Technologies, Inc., will do a presentation on the Company’s progress, including recent FDA 510(k) clearance for the Company’s proprietary PURE EP(TM) System, its core value proposition and benefits it aims to provide to the global and growing market of arrhythmias.

  • ACCESSWIRE5 months ago

    SeeThruEquity Issues Update on BioSig Technologies, Inc. (OTCQB: BSGM)

    NEW YORK, NY / ACCESSWIRE / June 18, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on BioSig Technologies, Inc. (BSGM). BioSig Technologies, Inc. (OTCQB: BSGM, "BioSig") is an innovative medical device company based in Minneapolis, MN. Led by its flagship product line, the PURE EP™ System (Precise Uninterrupted Real-time evaluation of Electrograms), BioSig is developing products with the potential to improve outcomes for patients with complex cardiac arrhythmias (heart rhythm disturbances).